Class I phosphoinositide 3-kinase beta and gamma isoforms (PI3K beta/gamma)

Class I phosphoinositide 3-kinase (PI3K) beta and gamma isoforms are lipid kinases that play distinct yet complementary roles in cellular signaling and disease pathogenesis. PI3K beta (p110beta) is ubiquitously expressed and is uniquely regulated by both receptor tyrosine kinases and G-protein coupled receptors, making it a critical driver in PTEN-deficient tumors. It also serves as a key mediator of platelet aggregation and arterial thrombosis, presenting a target for cardiovascular therapies. PI3K gamma (p110gamma) is primarily restricted to the hematopoietic system, where it mediates GPCR-driven leukocyte recruitment and inflammatory responses. In oncology, PI3K gamma promotes an immunosuppressive tumor microenvironment by regulating the polarization of myeloid cells toward a pro-tumor phenotype. Dual inhibition of these isoforms is a therapeutic strategy designed to simultaneously disrupt oncogenic survival pathways and reprogram the immune landscape to enhance anti-tumor responses. This approach is also being investigated for the treatment of chronic inflammatory disorders like rheumatoid arthritis and asthma. Clinical development of dual beta/gamma inhibitors aims to improve therapeutic efficacy while managing isoform-specific toxicities such as bleeding risks and immune-related adverse events.

Other names

p110beta/p110gammaPIK3CB/PIK3CGClass I PI3K beta and gammaPI3K beta/gamma dual targetPhosphoinositide 3-kinase beta and gamma

Inhibition of the ATP-binding site of the p110beta and p110gamma catalytic subunits of Class I phosphoinositide 3-kinases, preventing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and thereby suppressing downstream AKT/mTOR signaling pathways.